Skip to main content
Review time for Samsung's cancer drug extended by FDA

The FDA required an extension of three months to review Samsung Bioepis' biologics license application for cancer drug SB3, a biosimilar of Roche Holding unit Genentech's Herceptin, or trastuzumab. The agency is expected to give its decision in January.

Full Story: